Contineum Therapeutics, Inc.
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2017-01-01
- Employees
- 31
- Market Cap
- $511.1M
- Website
- http://www.contineum-tx.com
Contineum Therapeutics On Track for Key Clinical Milestones with PIPE-791 and PIPE-307 Programs
Contineum Therapeutics expects topline data from its PIPE-791 Phase 1b PET trial in Q2 2025 and PIPE-307 Phase 2 VISTA trial for relapsing-remitting multiple sclerosis in H2 2025, affirming its clinical development timeline.
Contineum Therapeutics Completes Enrollment in Phase 2 Trial of PIPE-307 for Relapsing-Remitting Multiple Sclerosis
Contineum Therapeutics has completed enrollment of 168 patients in its Phase 2 VISTA trial evaluating PIPE-307 for relapsing-remitting multiple sclerosis (RRMS).
Contineum Therapeutics Initiates Dosing in Phase 1b Trial of PIPE-791 for Multiple Sclerosis
Contineum Therapeutics has commenced patient dosing in a Phase 1b clinical trial evaluating PIPE-791, an LPA1 receptor antagonist, for the treatment of relapsing-remitting multiple sclerosis (RRMS).
IPF Drug Development Heats Up with Novel Targets and Clinical Advances
• Refoxy Pharma secured $9.58 million to advance its FOXO3-targeting IPF drug, RP-01, aiming to modulate tissue repair mechanisms. • Boehringer Ingelheim plans to submit an NDA for nerandomilast after a successful Phase 3 trial showing improved lung function in IPF patients. • Endeavor BioMedicines' ENV-101 and Insilico Medicine's ISM001-055 demonstrate promising results in improving lung function and reducing fibrosis in Phase 2 trials. • Bristol Myers Squibb's BMS-986278, an LPA1 antagonist, received FDA Breakthrough Therapy Designation after reducing the rate of FVC decline by 69% in a Phase 2 study.